News - Stealth BioTherapeutics Inc.

Stealth BioTherapeutics to Attend Upcoming Investor Conferences

BOSTON , Sept. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of no...

Press Release / September 20, 2019

Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer

BOSTON , Sept. 3, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of nove...

Press Release / September 03, 2019

Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights

BOSTON , Aug. 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization...

Press Release / August 14, 2019

Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders

BOSTON , July 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel the...

Press Release / July 02, 2019

Stealth Biotherapeutics to Present at Upcoming Investor Conferences

BOSTON , May 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of nove...

Press Release / May 30, 2019

Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights

BOSTON , May 15, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization ...

Press Release / May 15, 2019

Stealth BioTherapeutics to Present at UBS Global Healthcare Conference

BOSTON , May 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Press Release / May 14, 2019

Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions

BOSTON , April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Press Release / April 30, 2019

Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy

BOSTON , April 25, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of ...

Press Release / April 25, 2019

Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial

BOSTON , April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Press Release / April 16, 2019

Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights

BOSTON , April 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization o...

Press Release / April 04, 2019

Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference

BOSTON , April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel the...

Press Release / April 02, 2019

Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD

BOSTON , March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of ...

Press Release / March 28, 2019

Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option

BOSTON , March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization...

Press Release / March 04, 2019

People with Mitochondrial Disease Have Significant Medical Costs

A recent study published in Orphanet Journal of Rare Diseases reported that people with mitochondrial disease (mito) have significant medical costs, higher than that of the general population, and similar ...

Infographic / August 02, 2019

Stealth BioTherapeutics Announces Pricing of Initial Public Offering

BOSTON – February 14, 2019 – Stealth BioTherapeutics (Stealth), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving ...

Press Release / February 14, 2019

Press Release /

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

BOSTON – December 10, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food ...

Press Release / December 10, 2018

What is Barth Syndrome?

Barth syndrome is a rare, genetic, mitochondrial disorder causing metabolic abnormalities that can lead to an enlarged and weakened heart (cardiomyopathy), muscle weakness and fatigue (skeletal muscle ...

Infographic / August 16, 2018

Stealth BioTherapeutics Expands Pipeline, Advances New Compound

Stealth BioTherapeutics accelerates the development of a new pipeline candidate into Investigational New Drug enabling studies by leveraging Evotec’s INDiGO platform BOSTON – August 14, 2018 – Stealth ...

Press Release / August 14, 2018

Stealth BioTherapeutics Announces $100m Financings to Advance Clinical Development of Elamipretide and Pipeline

BOSTON – June 18, 2018 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for the treatment of mitochondrial dysfunction, ...

Press Release / June 18, 2018

The Journey to Diagnosis for People with Mitochondrial Disease

Infographic / June 11, 2018 A recent study published in Neurology: Genetics documented the complex journey to diagnosis for ...

Press Release / June 11, 2018

Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Leber’s Hereditary Optic Neuropathy

BOSTON – April 30, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced that the U.S. Food and Drug ...

Press Release / April 30, 2018

Stealth BioTherapeutics Granted Orphan Drug Designation for Elamipretide for Treatment of Barth Syndrome

BOSTON – April 9, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and ...

Press Release / April 09, 2018

MMPOWER Data Published in Neurology

We are pleased to share that the prestigious peer-reviewed publication Neurology recently publishedPhase 1/2 safety and efficacy data from the MMPOWER trial, which studied elamipretide versus placebo in ...

Press Release / March 29, 2018

Stealth BioTherapeutics Completes Enrollment of Study for the Treatment of Barth Syndrome

Top-line data expected by the end of 2018 BOSTON – March 6, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational therapeutics to treat mitochondrial ...

Press Release / March 06, 2018

Press Release /

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy

BOSTON – December 18, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food ...

Press Release / December 18, 2017

Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome

BOSTON – November 27, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food ...

Press Release / November 27, 2017

Stealth BioTherapeutics Initiates Phase 3 Study of Elamipretide in Patients with Primary Mitochondrial Myopathy

BOSTON, Nov. 6, 2017 /PRNewswire/ — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation ...

Press Release / November 06, 2017

Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy

BOSTON – October 2, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and ...

Press Release / October 02, 2017

Stealth BioTherapeutics Announces New Appointments to its Board of Directors

BOSTON – August 7, 2017 – Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced the appointment of three ...

Press Release / August 07, 2017

Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients with Barth Syndrome

Study will evaluate elamipretide in rare genetic mitochondrial disease characterized by muscle weakness, cardiac abnormalities, recurrent infections and delayed growth BOSTON – July 19, 2017 – Stealth ...

Press Release / July 24, 2017

Stealth BioTherapeutics Presents Phase 2 Data From MMPOWER-2 Continuation Trial Supporting Phase 3 Development of Elamipretide in Primary Mitochondrial Myopathy

Press Release / June 29, 2017 BOSTON - JUNE 29, 2017- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced ...

Press Release / June 29, 2017

Stealth BioTherapeutics to Present Top-Line Data From MMPOWER-2 Phase 2 Continuation Trial at Mitochondrial Medicine Symposium 2017

MMPOWER-2 assessed once daily dosing, tolerability and efficacy of elamipretide in patients who completed the MMPOWER clinical trial Company to feature presentation from primary mitochondrial myopathy ...

Press Release / June 15, 2017

Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy

Study results to inform design and appropriate patient population for interventional Phase 3 clinical trial BOSTON – March 2, 2017 – Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical ...

Press Release / May 02, 2017

Stealth BioTherapeutics Initiates Phase 1/2 Trial of SBT-20 in Patients With Early Stage Huntington’s Disease

SBT-20 is the second investigational compound from Stealth’s mitochondrial platform Trial results to inform development plan for targeting mitochondrial dysfunction in neurodegenerative diseases BOSTON ...

Press Release / May 02, 2017

Stealth BioTherapeutics Announces New Appointments to Senior Leadership Team

Doug Weaver named Chief Medical Officer, Daniel Geffken named interim Chief Financial Officer and Jim Carr promoted to Chief Clinical Development Officer BOSTON – January 19, 2017 – Stealth BioTherapeutics ...

Press Release / January 19, 2017

Stealth BioTherapeutics to Present at 28th Annual Piper Jaffray Healthcare Conference

BOSTON – November 28, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, ...

Press Release / November 28, 2016

Stealth BioTherapeutics Announces Positive Phase 2 Clinical Trial Findings for Patients Undergoing Renal Angioplasty

Data support company’s cardiorenal program, including three ongoing heart failure trials Single elamipretide infusion improves kidney microvasculature and function after renal artery angioplasty BOSTON ...

Press Release / November 18, 2016

Stealth BioTherapeutics Initiates Phase 1 Study of Elamipretide in Dry Age-Related Macular Degeneration

Top-line data from study evaluating elamipretide in patients with dry age-related macular degeneration expected mid-year 2017 BOSTON – November 14, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage ...

Press Release / November 14, 2016

Stealth BioTherapeutics to Present at Stifel 2016 Healthcare Conference

BOSTON – November 8, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, ...

Press Release / November 09, 2016

Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

Late-breaking poster presents data from elamipretide clinical trial in chronic kidney disease patients at risk of acute kidney injury BOSTON – November 7, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage ...

Press Release / November 07, 2016

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Patients Hospitalized with Congestive Heart Failure

Top-line results anticipated in second half of 2017 BOSTON – October 25, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial ...

Press Release / October 25, 2016

Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly

Trial evaluating treatment with investigational drug, elamipretide, demonstrated improved mitochondrial function by increasing energy production after single treatment BOSTON – September 19, 2016 – Stealth ...

Press Release / September 19, 2016

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease

Study will evaluate the long-term safety, tolerability and efficacy of elamipretide in patients who completed the Phase 2 MMPOWER study BOSTON – September 12, 2016 – Stealth BioTherapeutics (Stealth), ...

Press Release / September 12, 2016

Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

BOSTON – September 6, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Stealth Chief ...

Press Release / September 06, 2016

Stealth BioTherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide for the Treatment of Heart Failure

Trials to evaluate potential treatment option for heart failure patients with either reduced or preserved ejection fraction BOSTON – June 27, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage ...

Press Release / June 27, 2016

Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial

Positive Phase 2 data in rare disease trial lead to extension study and planning for Phase 3 BOSTON – June 17, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing ...

Press Release / June 17, 2016

At the Heart of Elamipretide in Heart Failure

On May 23rd, Brian Stauffer, M.D., cardiologist at the University of Colorado, presented new pre-clinical data examining the effects of elamipretide in human heart cells at Heart Failure 2016 in Florence, ...

Press Release / June 10, 2016

Stealth BioTherapeutics Reports Positive Results for Primary Mitochondrial Myopathy Trial

Trial evaluating treatment with elamipretide in rare disease meets efficacy and safety endpoints Data to be presented at Mitochondrial Medicine 2016 on Friday, June 17 at 8:10 a.m. PT BOSTON – June 6, ...

Press Release / June 06, 2016

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber’s Hereditary Optic Neuropathy

Trial augments ongoing clinical development program for rare genetic mitochondrial diseases BOSTON – June 01, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing ...

Press Release / June 01, 2016

What’s in a Name? The Root of Elamipretide

According to the World Health Organization and United States Adopted Names Council (USAN), a generic, or nonproprietary, name should be simple, informative and unique, and based on pharmacological and/or ...

Press Release / May 05, 2016

Stealth BioTherapeutics announces presentation of elamipretide data at ACC

Trial results support further study of elamipretide in heart failure BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs ...

Press Release / April 03, 2016

Stealth BioTherapeutics Initiates Phase 2 Clinical Study of Elamipretide in Fuchs’ Corneal Endothelial Dystrophy

Top-line data expected Q3 2016 for mitochondria-targeted treatment for debilitating eye condition BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company ...

Press Release / March 08, 2016

Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief ...

Press Release / March 01, 2016

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing ...

Press Release / January 07, 2016

The Site of Intracellular Metabolism May Be a Relevant Drug Target in Dry AMD

In the May/June cover story of Retina Today, Scott W. Cousins, MD, offers insights into how our investigational mitochondrial targeted drug Ocuvia (MTP-131) may help treat age-related macular degeneration ...

Press Release / September 09, 2015

Stealth BioTherapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference

Corporate Presentation on Wednesday, July 8th, 2015 at 9:30 AM ET BOSTON – July 7, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial ...

Press Release / July 07, 2015

Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating ...

Press Release / June 25, 2015

Stealth BioTherapeutics Presents at 2015 United Mitochondrial Disease Foundation National Symposium

Orphan mitochondrial disease program highlighted during annual meeting Boston, MA – June 22, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating ...

Press Release / June 22, 2015

Stealth BioTherapeutics to Present at Jefferies 2015 Healthcare Conference

Presentation will be on Monday, June 1st, 2015 at 10:30 AM ET Boston, MA – May 27, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial ...

Press Release / May 27, 2015

Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a ...

Press Release / April 27, 2015

Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

Promising heart failure results support strategic focus of Stealth’s cardio-renal program Boston, MA — March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing ...

Press Release / March 15, 2015

Stealth BioTherapeutics Presents at NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI Boston, MA — February 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical ...

Press Release / February 23, 2015

Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

The conferences will take place on Monday, March 2, 2015 in Boston and Tuesday, March 10, 2015 in Miami Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical ...

Press Release / February 23, 2015

Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases

Trial is one of the first to study Mitochondrial Myopathy, a disorder common to over 270 genetic mitochondrial diseases Boston, MA – February 17, 2015 – Stealth BioTherapeutics (Stealth) today announced ...

Press Release / February 17, 2015

Stealth BioTherapeutics Announces Promising Data on Ocuvia at 2015 Angiogenesis Conference

Ocuvia shows promise in dry age-related macular degeneration (AMD) studies Boston, MA — February 11, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug ...

Press Release / February 13, 2015

Stealth BioTherapeutics to Present at the 2015 Leerink Global Healthcare Conference

Presentation will be on Wednesday, February 11, 2015 at 2:15pm EST Boston, MA – February 4, 2015 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing ...

Press Release / February 04, 2015

Stealth Biotherapeutics Expands Clinical Development for Mitochondrial Therapies

Funding grows to more than $100M Boston, MA — January 9, 2015 — (BUSINESS WIRE) — Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates ...

Press Release / January 09, 2015

Stealth BioTherapeutics Announces the Appointment of Mark P. Colonnese as Chief Financial Officer

Mark Colonnese will lead the Company’s financial and capital markets strategy Boston, MA — January 8, 2015 — (BUSINESS WIRE) — Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical ...

Press Release / January 08, 2015

Stealth BioTherapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference on December 3, 2014

Presentation will be on Wednesday, December 3, 2014 at 10:50 a.m. EST Newton, MA – November 25, 2014 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed ...

Press Release / November 25, 2014

Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress

Researchers reported on recent studies demonstrating Bendavia’s ability to improve cardiac function Boston, MA — June 24, 2013—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ ...

Press Release / June 24, 2013

Stealth Peptides Reports Successful Clinical Study of Oral Bendavia

Positive Data Broadens Bendavia’s Potential for Chronic Heart Failure and Cardioprotection BOSTON, MA, January 22, 2013–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical ...

Press Release / January 22, 2013

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury

Clinical Study Broadens Bendavia’s Potential for Acute and Chronic Kidney Disease Boston, MA — January 16, 2013—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company ...

Press Release / January 16, 2013

Drs. Hani Sabbah, David Brown, Sharon Hale and Robert Kloner Present Bendavia Research at 2012 American Heart Association Annual Meeting

Doctors reported on studies showing Bendavia’s ability to preserve cardiac function Boston, MA — November 26, 2012—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ ...

Press Release / November 26, 2012

Top Researchers Present Promising Bendavia Findings at Annual American Society of Nephrology Meeting

Top researchers presented findings showing Bendavia reduced renal and myocardial injury Boston, MA – November 19, 2012–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical ...

Press Release / November 19, 2012

Stealth Peptides Co-Sponsors Cardioprotection Colloquium

Colloquium featured the latest innovations in cardioprotection and the most up-to-date research Boston, MA — November 2, 2012 — Stealth Peptides co-sponsored the 2012 Cardioprotection Colloquium held at ...

Press Release / November 02, 2012

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Cardiovascular Disease and Reperfusion Injury

First patient was enrolled in its multinational Phase II clinical study today Boston, MA – June 25, 2012–(BUSINESS WIRE)–Stealth Peptides Incorporated (Stealth), a privately held biopharmaceutical company ...

Press Release / June 25, 2012

Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia

Announced the results from three Phase I clinical trials of Bendavia Boston, MA – April 9, 2012–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative ...

Press Release / April 09, 2012

Dr. Robert Kloner Presents Bendavia Research At 2011 American Heart Association Annual Meeting

Study findings presented during the American Heart Association’s (AHA) annual meeting Boston, MA — November 28, 2011—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical ...

Press Release / November 28, 2011

Researchers Present Promising Bendavia Findings at Annual American Society of Nephrology Meeting

Bendavia study findings presented during the annual American Society of Nephrology (ASN) meeting Boston, MA – November 15, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical ...

Press Release / November 15, 2011